US Peptide Science Research Team
July 3, 2026
Recent high-profile endorsements have elevated GLP-1 peptides into mainstream wellness conversation. Tennis champion Serena Williams publicly attributed improved mobility and weight management to GLP-1 therapy, describing her experience in a 2025 Super Bowl advertisement for Ro, a telehealth prescriber of semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound). While such visibility has increased awareness of these therapeutics, it has also conflated distinct use cases: clinical treatment of metabolic disease versus cosmetic body optimization. This FAQ addresses the science underlying GLP-1 peptides, separates evidence-based applications from marketing claims, and clarifies what research actually demonstrates about safety, efficacy, and long-term outcomes.
GLP-1 (glucagon-like peptide-1) is a naturally occurring incretin hormone produced by L-cells in the small intestine in response to nutrient intake. Endogenous GLP-1 has a half-life of approximately 2 minutes and is rapidly degraded by the enzyme DPP-4, limiting its therapeutic utility in native form.
Pharmaceutical GLP-1 agonists are structurally modified to resist DPP-4 degradation, extending half-life to 7 days (semaglutide) or 5 days (tirzepatide). These modified peptides activate GLP-1 receptors throughout the body, triggering multiple metabolic effects:
These mechanisms address multiple pathophysiologic drivers of obesity and type 2 diabetes, which explains their clinical potency relative to earlier pharmacotherapies.
Peptides are short chains of amino acids (typically 2–50 residues) that function as signaling molecules. In research and therapeutic contexts, peptides serve diverse roles: growth hormone secretagogues like CJC-1295/ipamorelin are investigated for endogenous growth hormone stimulation; recovery-focused peptides like BPC-157 are investigated for tissue healing; and metabolic peptides like GLP-1 agonists regulate glucose homeostasis and appetite.
The distinction between approved therapeutics (semaglutide, tirzepatide) and research compounds is regulatory and evidentiary. Approved GLP-1 agonists have undergone Phase 3 randomized controlled trials demonstrating safety and efficacy. Emerging peptides like retatrutide (a triple GLP-1/GIP/glucagon agonist currently in Phase 3 development) show promise but lack the clinical data necessary for regulatory approval.
Semaglutide and tirzepatide represent the most potent pharmaceutical weight-loss interventions documented to date.
Semaglutide (Wegovy): The STEP 1 trial, a 68-week Phase 3 randomized controlled trial, demonstrated 14.9% mean weight loss at the 2.4 mg weekly dose versus 2.4% with placebo—a 6-fold difference. This trial established semaglutide's efficacy in adults with obesity or overweight with weight-related comorbidities.
Tirzepatide (Zepbound): A dual GLP-1/GIP agonist manufactured by Eli Lilly, tirzepatide achieved 20.9% mean weight loss at 72 weeks (15 mg weekly dose) versus 3.1% placebo in the SURMOUNT-1 trial—the highest weight loss achieved by any pharmaceutical intervention to date. Head-to-head comparisons (SURMOUNT-5) showed tirzepatide 15 mg produced significantly greater weight loss than semaglutide 2.4 mg, establishing tirzepatide's superior efficacy within the GLP-1 class.
Cardiovascular outcomes: The SELECT trial, published in 2024, demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in overweight or obese adults without diabetes receiving semaglutide, making it the first anti-obesity medication to show cardiovascular benefit independent of weight loss alone. This finding shifted GLP-1 positioning from weight-loss drug to cardiovascular risk modifier.
Yes. The SUSTAIN program (semaglutide) and SURPASS trials (tirzepatide) consistently demonstrated HbA1c reductions of 1.5–1.8% across multiple trials, establishing both compounds as effective glucose-lowering agents. For patients with type 2 diabetes and obesity, GLP-1 agonists address both conditions simultaneously.
This is the most clinically significant and underreported aspect of GLP-1 therapy. Across STEP 1 (semaglutide) and SURMOUNT trials (tirzepatide), lean body mass comprises approximately 25–40% of total weight lost. According to a 2025 meta-analysis in the nature.com International Journal of Obesity, semaglutide demonstrated the most significant reduction in absolute lean mass, with a loss of −5.44 kg (95% CI: −7.07 to −3.81; p < 0.00001). In absolute terms, this represents a clinically meaningful reduction in lean tissue.
This ratio reflects a fundamental metabolic reality: when caloric intake decreases, the body mobilizes both adipose and lean tissue for energy. GLP-1 drugs achieve weight loss primarily through appetite suppression and delayed gastric emptying—they do not selectively target fat stores.
According to research published in onlinelibrary.wiley.com, clinical trial participants receiving GLP-1 agonists for obesity treatment lost approximately 10% or more of their muscle mass during 68- to 72-week interventions, an amount equivalent to approximately 20 years of age-related muscle loss. For older adults, this concern becomes primary: muscle loss accelerates sarcopenia, increases fracture risk, and reduces resting metabolic rate.
Resistance training combined with adequate protein intake may slow lean mass loss during GLP-1 therapy. Research from onlinelibrary.wiley.com indicates that "the ability to maintain muscle mass during caloric restriction-induced weight reduction is influenced by two key factors: nutrition and physical exercise," and that "concurrent physical activity, especially resistance training, has been shown to effectively minimize loss of muscle mass and function during weight reduction therapy."
However, whether resistance training fully prevents lean mass loss during GLP-1 agonist use is not yet definitively established in peer-reviewed literature. The evidence supports mitigation rather than complete prevention. Clinical practice guidelines increasingly recommend concurrent resistance training and protein supplementation as standard components of GLP-1 therapy, yet this practice remains inconsistent across telehealth and primary care settings.
Weight regain occurs rapidly and substantially. STEP 1 extension data tracked participants after semaglutide discontinuation and found approximately two-thirds of lost weight was regained within one year. SURMOUNT-4 (tirzepatide) showed similar patterns. A BMJ meta-analysis (2025) confirmed this pattern across multiple GLP-1 agonists: most weight returns within 12–18 months of stopping.
This pharmacodynamic reality has led to the medical framing of obesity as a chronic condition requiring ongoing treatment, similar to hypertension. It also establishes that GLP-1 therapy may require sustained use rather than time-limited intervention—at typical list prices of $1,000–1,500 monthly without insurance coverage.
No. It means GLP-1 drugs work as appetite suppressants and metabolic modulators, not as permanent metabolic reset mechanisms. For patients with obesity-related comorbidities (cardiovascular disease, type 2 diabetes, sleep apnea), sustained weight reduction—even if weight regain occurs after discontinuation—provides documented clinical benefit. The SELECT trial's cardiovascular findings support this.
The distinction matters: GLP-1 drugs are effective treatments for chronic metabolic disease. They are not cures, and they are not appropriate as short-term cosmetic interventions.
Yes, based on publicly available information. Williams stated she sought GLP-1 therapy after the birth of her second child in 2023, describing weight that was "not healthy" for her at that time. She lost 34 pounds and reported improved mobility and steadier blood glucose during training. She emphasized improved joint function at her lower weight—a clinically plausible benefit, as reduced body mass decreases mechanical stress on weight-bearing joints.
Williams is not promoting GLP-1 drugs as performance-enhancing agents; she is promoting them for FDA-approved uses (weight management, metabolic health). Her experience aligns with clinical indications: an individual with documented excess weight seeking to restore prior functional capacity.
Celebrity endorsements have normalized GLP-1 therapy across populations that do not meet clinical criteria for obesity. A UCSD Guardian analysis framed this as a "prescription-to-trend" pipeline: social media accelerates demand for medications among individuals without metabolic disease or obesity diagnosis.
The clinical distinction is stark:
| Medical Use | Cosmetic Use |
|---|---|
| BMI 30+ or 27+ with comorbidities | Often BMI <27 with no metabolic condition |
| Prescribed after lifestyle interventions fail | Sought as first-line approach |
| Monitored by endocrinologist with follow-up | Often obtained via telehealth without ongoing supervision |
| Combined with nutrition and exercise plans | Rarely paired with muscle preservation strategies |
| Insurance may cover eligible patients | Out-of-pocket ($1,000+/month) |
Cosmetic use in lean, metabolically healthy individuals exposes users to gastrointestinal side effects (nausea, vomiting, diarrhea, constipation), muscle loss, and cost without the compensatory cardiovascular or metabolic benefit that justifies these risks in obese populations. According to nature.com, the most common adverse events were gastrointestinal, with incidence higher with semaglutide (74.2% vs. 47.9% with placebo), liraglutide (53% vs. 8%), and tirzepatide (up to 81.8% vs. 72%).
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 development, retatrutide has demonstrated 28.7% mean weight loss in early trials—substantially greater than semaglutide or tirzepatide. However, Phase 3 data are incomplete, regulatory approval is pending, and long-term safety and lean mass loss profiles remain under investigation.
Retatrutide represents the trajectory of GLP-1 research: incremental refinement of receptor selectivity to maximize metabolic benefit while ideally minimizing adverse effects. Whether this triple agonist reduces lean mass loss relative to dual agonists is not yet established.
Research into peptides has expanded beyond GLP-1 agonists. Growth hormone secretagogues like CJC-1295/ipamorelin are investigated for lean mass preservation and recovery. Other peptides under research investigation include BPC-157 (studied for tissue healing), TB-500 (investigated for muscle recovery), and GHK-CU (explored for skin and tissue regeneration).
Critically, most non-GLP-1 peptides lack the clinical trial data supporting GLP-1 agonists. Cost, regulatory status, and evidence quality vary substantially. Researchers evaluating peptides for any application should prioritize peer-reviewed efficacy and safety data over marketing claims or celebrity endorsement.
GLP-1 peptides represent a genuine pharmacologic advance for treating obesity and type 2 diabetes, with documented cardiovascular benefits in appropriate populations. The clinical evidence is robust and specific: these drugs work for individuals with metabolic disease or obesity-related comorbidities.
However, celebrity visibility has obscured critical nuances. Lean body mass loss (25–40% of total weight lost) is substantial and requires active mitigation. Weight regain after discontinuation is rapid and near-universal. Long-term use may be the realistic model for sustained benefit. And cosmetic use in lean, metabolically healthy individuals lacks clinical justification and amplifies risk-to-benefit ratios.
For researchers evaluating GLP-1 peptides or emerging alternatives like retatrutide, the evidence base supports investigation in metabolically compromised populations with appropriate monitoring, concurrent resistance training, and protein supplementation. Off-label cosmetic use remains scientifically indefensible based on current data.